Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
house dust mite allergen sublingual immunotherapy
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
House dust mite allergen sublingual immunotherapy is an allergen-specific immunotherapy (AIT) product developed by ARTU Biologicals Europe BV. It consists of allergen extracts derived from the house dust mites *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. Administered sublingually, the drug aims to desensitize the immune system to house dust mite (HDM) allergens, thereby reducing symptoms of allergic rhinitis and associated asthma. The product works by modulating the T-cell response, shifting the immune profile from a Th2-mediated allergic response toward a regulatory T-cell (Treg) and Th1-mediated profile, which reduces IgE-mediated allergic inflammation. It has been evaluated in randomized, double-blind, placebo-controlled trials, specifically in children aged 6–18 years in primary care settings in the Netherlands.
- Brand names
- ASACIMUN SL
- Other names
- HDM SLIThouse dust mite sublingual immunotherapy
02
Targets
TCR (T cell antigen receptor complex)TLR4 (Toll-like receptor 4)BCR (Immunoglobulin G B Cell Receptor)CLR (C-type lectin receptors)HLA-DR (Human leukocyte antigen DR)
Beyond the preview
Go deeper on house dust mite allergen sublingual immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on house dust mite allergen sublingual immunotherapy.